Inclusion Criteria:

• Subject is able to provide, personally signed, and dated informed consent to participate in the study or will have a legally authorized representative (LAR) sign the informed consent on his or her behalf before completing any study related procedures.
• Male or female ≥ 18 years of age.
• Has an established diagnosis of focal or generalized epilepsy or focal and generalized epilepsy with a documented history of predictable seizure episodes that includes at least one of the following:
  • Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum duration of 5 minutes;
  • Episodes of a prolonged focal seizure with a minimum duration of 3 minutes;
  • Episodes of multiple (≥2) seizures within a 2-hour time period,
• Prior to randomization, has experienced ≥4 seizure episodes with predictable pattern during the last 4 weeks (qualification period) and no more than one week without a predictable seizure episode before entry into the in-patient unit.
• Female participants (if of child-bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method throughout the study and for 1 week following the end of the study. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine device (IUD), surgical sterilization, and progestin implant or injection. Prohibited methods include: the rhythm method, withdrawal, condoms alone, or diaphragm alone.
• Subject is able to comply by the requirements of the protocol, particularly the requirements and specific Institution policies during the in-patient stay.

Exclusion Criteria:

• History or diagnosis of non-epileptic seizures (e.g., metabolic or pseudo-seizures).
• History of status epilepticus in the 6 months prior to Screening.
• Has a progressive neurological disorder such as brain tumor, demyelinating disease, or degenerative central nervous system (CNS) disease that is likely to progress in the next 3 months.
• Use of strong CYP 3A4 inhibitors; including azole antifungal agents (e.g., etoconazole, itraconazole), nefazodone, fluvoxamine, cimetidine, HIV protease inhibitors (e.g., ritonavir).
• Has severe chronic cardio-respiratory disease.
• History of HIV-positivity.
• Pregnant or breast-feeding.
• Clinically significant renal or hepatic insufficiency (hepatic transaminases >2 times the upper limit of normal (ULN) or creatinine ≥ 1.5 x ULN).
• History of acute narrow angle glaucoma, Parkinson's disease, hydrocephalus, or history of significant head trauma.
• Subjects who use medications to treat airways disease, such as asthma or COPD or have any acute respiratory signs/symptoms (e.g., wheezing).
• Use of any investigational drug within 30 days or 5 half-lives of the investigational drug prior to administration of study medication, whichever is longer.
• A history within the past 1 year of drug or alcohol dependence or abuse.
• Positive urine screen for drugs of abuse at Screening (positive Cannabis/Cannabinol results are acceptable if there is a documented history of stable use for medical purposes).
• Known allergy or hypersensitivity to alprazolam.
• History of glaucoma.
• Subjects who currently have an active major psychiatric disorder where changes in pharmacotherapy are needed or anticipated during the study.
• Hypotension (systolic blood pressure ≤90 mm Hg, diastolic blood pressure ≤50 mm Hg), or hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥100 mm Hg) measured while seated at screening or baseline.
• Significant hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease and congestive heart failure), endocrine, neurologic or hematologic disease.
• Subjects who, in the opinion of the Investigator, should not participate in the study for any reason, including if there is a question about the stability or capability of the subject to comply with the trial requirements.